| scholarly article | Q13442814 |
| P50 | author | Julie Decock | Q37843331 |
| P2093 | author name string | P Neven | |
| H Wildiers | |||
| R Paridaens | |||
| M R Christiaens | |||
| M Drijkoningen | |||
| W Hendrickx | |||
| P2860 | cites work | Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients | Q28366039 |
| New functions for the matrix metalloproteinases in cancer progression | Q29547738 | ||
| Regulation of matrix metalloproteinase expression in tumor invasion. | Q33605726 | ||
| Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications | Q33692926 | ||
| Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis | Q34372081 | ||
| Metalloproteinases and their inhibitors in angiogenesis. | Q35571165 | ||
| Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by use of an extravasation model | Q35785948 | ||
| Prognostic factors and treatment decisions in axillary-node-negative breast cancer | Q36154245 | ||
| Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma | Q36671053 | ||
| Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera | Q36694831 | ||
| EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. | Q38950448 | ||
| Identification and validation of an ERBB2 gene expression signature in breast cancers | Q40595739 | ||
| Growth factors in breast cancer | Q40928040 | ||
| Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis | Q40994611 | ||
| Invasive phenotype of MCF10A cells overexpressing c-Ha-ras and c-erbB-2 oncogenes. | Q41260117 | ||
| Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy | Q43540159 | ||
| Use of citrate to minimize neutrophil matrix metalloproteinase-9 in human plasma | Q44641391 | ||
| A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma | Q44761893 | ||
| Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. | Q46871097 | ||
| The hemopexin-like domain (C domain) of human gelatinase A (matrix metalloproteinase-2) requires Ca2+ for fibronectin and heparin binding. Binding properties of recombinant gelatinase A C domain to extracellular matrix and basement membrane componen | Q52524228 | ||
| Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood | Q62632545 | ||
| The C-terminus of type I collagen is a major binding site for heparin | Q70139679 | ||
| M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer | Q70521319 | ||
| c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties | Q72680125 | ||
| Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities | Q73148838 | ||
| MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma | Q73551534 | ||
| Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors | Q73595181 | ||
| Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients | Q73679099 | ||
| Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands | Q73876250 | ||
| Serum levels of matrix metalloproteinase 2 in patients with breast cancer | Q74574408 | ||
| Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma | Q77308636 | ||
| P433 | issue | 6 | |
| P921 | main subject | lymph node | Q170758 |
| P304 | page(s) | 495-502 | |
| P577 | publication date | 2005-01-01 | |
| P1433 | published in | Clinical & Experimental Metastasis | Q13470030 |
| P1476 | title | Plasma gelatinase levels in patients with primary breast cancer in relation to axillary lymph node status, Her2/neu expression and other clinicopathological variables. | |
| P478 | volume | 22 |
| Q37277274 | Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer |
| Q49191191 | Prognostic significance of plasma matrix metalloprotease-2 in pancreatic cancer patients |
| Q36847236 | Significance of Matrix Metalloproteinase 9 Expression as Supporting Marker to Cytokeratin 19 mRNA in Sentinel Lymph Nodes in Breast Cancer Patients |
| Q34284339 | The association between the preoperative serum levels of lipocalin-2 and matrix metalloproteinase-9 (MMP-9) and prognosis of breast cancer |
Search more.